Compile Data Set for Download or QSAR
maximum 50k data
Found 11 of ki for monomerid = 108102
TargetPlasminogen(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108102(US8598206, Table 6, 11)
Affinity DataKi:  1.20nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108102(US8598206, Table 6, 11)
Affinity DataKi:  1.30nMAssay Description:The inhibitory effect for the individual enzymes was determined in analogy to a previously disclosed method (Stürzebecher et al., J. Med. Chem.,...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCoagulation factor XII(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108102(US8598206, Table 6, 11)
Affinity DataKi:  680nMAssay Description:Inhibition of human alpha-FXIIa was determined by the method described in [0092]-[0098] using activated human alpha-Factor XII (activated Hageman Fac...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVitamin K-dependent protein C(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108102(US8598206, Table 6, 11)
Affinity DataKi:  1.20E+3nMAssay Description:Inhibition of human aPC was determined by the method described in [0092]-[0098] using human activated protein C from Enzyme Research Laboratories at ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108102(US8598206, Table 6, 11)
Affinity DataKi:  1.40E+3nMAssay Description:Inhibition of human FXIa was determined by the method described in [0092]-[0098] using activated human Factor XI from Enzyme Research Laboratories at...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCoagulation factor X(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108102(US8598206, Table 6, 11)
Affinity DataKi:  1.60E+3nMAssay Description:Inhibition of human FXa was determined by the method described in [0092]-[0098] using activated human Factor X from Enzyme Research Laboratories at 5...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTranscription initiation factor IIA subunit 1(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108102(US8598206, Table 6, 11)
Affinity DataKi:  4.50E+3nMAssay Description:Inhibition of human FIIa was determined by the method described in [0092]-[0098] using human alpha-thrombin from Enzyme Research Laboratories at 0.1 ...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTissue-type plasminogen activator(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108102(US8598206, Table 6, 11)
Affinity DataKi:  4.70E+3nMAssay Description:Inhibition of human t-PA was determined by the method described in [0092]-[0098] using recombinant human tissue-type plasminogen activator (Actilyse&...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement C1s subcomponent(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108102(US8598206, Table 6, 11)
Affinity DataKi:  2.00E+4nMAssay Description: Inhibition of human C1s was determined by the method described in [0092]-[0098] using native human activated C1s complement component from Calbioche...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetComplement C1r subcomponent(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108102(US8598206, Table 6, 11)
Affinity DataKi: >5.00E+4nMAssay Description:Inhibition of human C1r was determined by the method described in [0092]-[0098] using native human activated C1r complement component from Calbiochem...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
The Medicines Company (Leipzig)

US Patent
LigandPNGBDBM108102(US8598206, Table 6, 11)
Affinity DataKi: >1.00E+5nMAssay Description:Inhibition of human t-PA was determined by the method described in [0092]-[0098] using recombinant human tissue-type plasminogen activator (Actilyse&...More data for this Ligand-Target Pair
In DepthDetails US Patent